Teva Pharmaceutical Industries Limited

Generic drug volumes are relatively stable year to year, but pricing is subject to episodic competitive shocks, illustrated by the roughly $1.1 billion Revlimid generic competition headwind built into 2026 guidance. The innovative portfolio (AUSTEDO, AJOVY, UZEDY) adds a growing prescription-driven component but constitutes less than 20% of consolidated FY2025 revenue.

Teva's generics portfolio spans thousands of molecules across therapeutic categories, providing genuine product breadth. Growth is concentrated in two to three innovative products (AUSTEDO, AJOVY, UZEDY), and the strategic narrative depends disproportionately on these brands performing as projected through 2030.

Revenue divides across three segments: United States (approximately 46%), Europe (approximately 29%), and International (approximately 25%), with no single non-US country dominant. The US segment's near-majority share exposes consolidated results to US regulatory dynamics, including IRA price negotiations, Medicaid policy shifts, and pharmaceutical antitrust proceedings.

Pharmaceutical manufacturing requires substantial capital and labor, limiting structural operating leverage. The transition toward higher-margin innovative medicines provides incremental improvement, with management targeting a 30% operating profit margin by 2027, but the manufacturing cost base is not asset-light and scalability is constrained relative to pure-play biotech peers.

More than 80% of FY2025 revenue derives from generic drugs sold through distributors at competitive market prices, creating a predominantly transactional revenue base with high substitutability. AUSTEDO and AJOVY provide repeat prescription dynamics with some clinical inertia but do not yet shift the consolidated quality profile materially.